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ABSTRACT 23 
 The mammalian host responds to viral infections by inducing expression of hundreds of 24 
interferon-stimulated genes (ISGs). While the functional significance of many ISGs has yet to be 25 
determined, their cell-type and temporal nature of expression suggests unique activities against 26 
specific pathogens. Using a combination of ectopic expression and gene silencing approaches 27 
in cell culture, we previously identified Ifi27l2a as a candidate antiviral ISG within neuronal 28 
subsets of the central nervous system (CNS) that restricts West Nile virus (WNV) infection, an 29 
encephalitic flavivirus of global concern. To investigate the physiological relevance of Ifi27l2a in 30 
the context of viral infection, we generated Ifi27l2a-/- mice. Although adult mice lacking Ifi27l2a 31 
were more vulnerable to lethal WNV infection, viral burden was greater only within the CNS, 32 
particularly in the brain stem, cerebellum, and spinal cord. Within neurons of the cerebellum and 33 
brain stem, in the context of WNV infection, a deficiency of Ifi27l2a was associated with less cell 34 
death, which likely contributed to sustained viral replication and higher titers in these regions. 35 
Infection studies in primary cell culture revealed that Ifi27l2a-/- cerebellar granule cell neurons 36 
and macrophages but not cerebral cortical neurons, embryonic fibroblasts, or dendritic cells 37 
sustained higher WNV infection compared to wild-type cells, and this difference was greater 38 
under conditions of IFN-β pretreatment. Collectively, these findings suggest that Ifi27l2a has an 39 
antiviral phenotype in subsets of cells, and that at least some ISGs have specific inhibitory 40 
functions in restricted tissues. 41 
42 
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IMPORTANCE STATEMENT 43 
 The interferon-stimulated gene, Ifi27l2a, is expressed differentially within the central 44 
nervous system upon interferon stimulation or viral infection. Prior studies in cell culture 45 
suggested an antiviral role for Ifi27l2a during infection by West Nile virus (WNV). To 46 
characterize its antiviral activity in vivo, we generated mice with a targeted gene deletion of 47 
Ifi27l2a. Based on extensive virological analyses, we determined that Ifi27l2a protects mice from 48 
WNV-induced mortality by contributing to the control of infection of the hindbrain and spinal 49 
cord, possibly by regulating cell death of neurons. This antiviral activity was validated in granule 50 
cell neurons derived from the cerebellum and in macrophages but was not observed in other 51 
cell types. Collectively, these data suggest Ifi27l2a contributes to innate immune restriction of 52 
WNV in a cell-type and tissue-specific manner.  53 
54 
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INTRODUCTION  55 
West Nile virus (WNV) is a positive-stranded, enveloped RNA virus that belongs to the 56 
Flavivirus genus of the Flaviviridae family. WNV and related flaviviruses typically are transmitted 57 
by arthropod vectors and include members that cause encephalitis (e.g., Japanese encephalitis 58 
virus (JEV), Saint Louis encephalitis virus (SLEV), and tick-borne encephalitis virus (TBEV)) or 59 
systemic and/or visceral disease (e.g., Dengue virus (DENV) and yellow fever virus (YFV)). 60 
WNV transmission occurs between Culex species mosquitoes and selected avian hosts, with 61 
incidental, dead-end infection of horses, humans, and other vertebrate animals. Humans can 62 
develop severe disease following WNV infection, as the virus can invade the central nervous 63 
system (CNS) and cause flaccid paralysis, meningitis, or encephalitis, often leading to long-term 64 
neurological sequelae or death (1). In the CNS, WNV replicates principally in neurons, and 65 
infection may lead to focal lesions, cell injury, and cell death within the brain and spinal cord (2-66 
4). Factors governing WNV entry into and replication within the CNS are complex, and include 67 
age of the host, genetic background (5-8), quality of the immune response, and integrity of the 68 
blood-brain barrier (for review, 9, 10-12).  69 
 In response to viral infections, most mammalian cells secrete type I interferon (IFN), 70 
which promotes an antiviral state in an autocrine and paracrine manner by inducing expression 71 
of hundreds of interferon-stimulated genes (ISGs). The gene signature and inhibitory activity 72 
promoted by type I IFNs vary depending on the cell type, specific viral pathogen, and possible 73 
pathogen-induced immune evasion mechanisms. Within the CNS, the innate immune response 74 
must balance the need to restrict virus infection while simultaneously protecting non-renewable 75 
neurons. Indeed, selected regions of the brain and CNS have evolved distinct antiviral programs 76 
and mechanisms to restrict infection of different RNA and DNA viruses (13-18). Neurons derived 77 
from the cerebral cortex are more permissive to infection by multiple viruses, with IFN-β 78 
pretreatment only minimally reducing infection of several viruses (14). In comparison, granule 79 
cell neurons (GCN) derived from the cerebellum are less permissive to viral infection at baseline 80 
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state and produce a stronger antiviral response following IFN-β pretreatment. Microarray 81 
analysis revealed differences in the basal and induced expression of ISGs in GCN compared to 82 
cortical neurons (CN) (14). As an example, Ifi27l2a is an ISG expressed at higher levels in GCN 83 
compared to CN under basal conditions, after IFN-β pretreatment, or following WNV infection. 84 
Ectopic expression of Ifi27l2a in CN suppressed infection of a neurotropic flavivirus (WNV) and 85 
coronavirus (murine hepatitis virus (MHV)) but not an alphavirus (Venezuelan equine 86 
encephalitis virus (VEEV)). Reciprocally, gene silencing of Ifi27l2a in GCN resulted in enhanced 87 
WNV infection (14).    88 
Ifi27l2a (also termed ISG12b) is a 7.9 kDa protein belonging to a larger family of genes 89 
that include related Ifi27/IFI27 genes, and the human IFI6-16 gene (19), which are distinguished 90 
by an “ISG12” motif of unknown function (20). Family members are small, highly hydrophobic 91 
and may be localized to either mitochondrial (21, 22) or nuclear membranes (23, 24), although 92 
the exact localization has not been fully elucidated. Several Ifi27 genes are IFN-inducible (19) 93 
yet others are not, and among the family members, some orthologs are not conserved across 94 
species. As an example, IFI6-16 is an IFI27 human gene family member that inhibits infection of 95 
YFV, WNV, and hepatitis C virus (HCV) (25-28), but does not have an apparent ortholog in 96 
mice. Although Ifi27l2a is induced broadly in peripheral organs after IFN stimulation, in the brain 97 
it is expressed in selected regions during development in an age-dependent manner (29) with 98 
high levels within the hippocampus (30). Cell culture studies have suggested that some Ifi27 99 
gene orthologs (e.g., ISG12a) promote apoptosis and cell death (21, 31, 32). 100 
Ifi27l2a and its closest orthologs have been evaluated as candidate antiviral genes. 101 
Despite the strong upregulation of Ifi27l2a mRNA in lung tissues, largely by infiltrating immune 102 
cells, Ifi27l2a-/- mice were not more susceptible to influenza A virus (IAV) infection than wild-type 103 
(WT) mice (33). In contrast, ectopic expression of human IFI27 inhibited HCV and Newcastle 104 
disease virus (NDV) infection in hepatocellular carcinoma cells; reciprocally, gene silencing of 105 
IFI27 resulted in increased HCV and NDV infection (28, 34). Apart from its possible antiviral 106 
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activity, Ifi27 genes may regulate inflammation, as mice lacking Ifi27l2a sustained less vascular 107 
injury (24) and exhibited less septic shock after administration of endotoxin (35). 108 
 To characterize further the antiviral effects of Ifi27l2a, we generated Ifi27l2a-/- mice 109 
directly in a C57BL/6 background. Ifi27l2a-/- GCN from the cerebellum and bone marrow-derived 110 
macrophages (Mφ) supported higher levels of WNV infection. Following infection with WNV in 111 
vivo, Ifi27l2a-/- mice exhibited increased mortality and higher viral burden in the cerebellum, 112 
brain stem, and spinal cord. The enhanced viral burden in the cerebellum and brain stem of 113 
Ifi27l2a-/- mice was associated with less death of neurons at early stages of CNS infection. Our 114 
findings suggest that Ifi27l2a contributes to an antiviral state against WNV within the CNS, and 115 
protects subsets of cell types and regions of the brain against infection.    116 
117 
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MATERIALS AND METHODS 118 
 Virus. A WNV-New York (WNV-NY) stock was generated in C6/36 Aedes albopictus 119 
cells (ATCC) from a single passage of strain 3000.0259 isolated from a mosquito in New York in 120 
2000 (36). The WNV Madagascar strain (WNV-MAD) stock was generated by passaging virus 121 
in Vero or C6/36 cells as described previously (37). WNV titers were assessed by plaque assay 122 
on BHK21-15 cells (38, 39). All virus stocks were stored at -80oC. 123 
 Mice. WT C57BL/6 mice were obtained from Jackson Laboratory (Bar Harbor, ME). 124 
Ifi27l2a-/- (ISG12b; 76933) mice were generated at Washington University after receiving 125 
heterozygous sperm from C57BL/6 containing a deleted gene (Ifi27l2atm1(KOMP)Vlcg) from the 126 
Knockout Mouse Project Repository (KOMP, University of California, Davis). Sperm was used 127 
for in vitro fertilization of eggs from C57BL/6 recipient female mice. Heterozygous Ifi27l2a+/- 128 
mice were backcrossed to establish the Ifi27l2a-/- colony. Ifi27l2a-/- mice produced normal litter 129 
sizes of expected Mendelian ratios, with all progeny appearing healthy. All animals were 130 
maintained in the pathogen-free animal facility of Washington University School of Medicine.   131 
 Mouse infection experiments. The experimental protocols were approved by the 132 
Institutional Animal Care and Use Committee at the Washington University School of Medicine 133 
(Assurance Number: A3381-01). Studies were performed on sex- and age-matched mice 134 
between 11 and 12 weeks of age, Peripheral infection was performed by subcutaneous 135 
inoculation into the footpad with 102 PFU of virus diluted in 50 μl Hank’s Balance Salt Solution 136 
(HBSS) with 1% heat-inactivated fetal bovine serum (HI-FBS). Survival analysis was followed 137 
for 30 days. For viral burden studies after subcutaneous infection, mice were sacrificed at days 138 
2, 4, 6, 8, 10, and 14 and peripheral organ and CNS tissues were collected following extensive 139 
perfusion with PBS, and stored at -80˚C. Serum was collected after cardiac puncture according 140 
to standard procedures. Intracranial infection was performed by injecting 101 PFU of WNV-NY or 141 
WNV-MAD in 10 μl HBSS supplemented with 1% HI-FBS. For analysis of viral burden after 142 
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intracranial infection, brain and spinal cord tissues were collected at 3 and 5 days and 143 
processed as described for tissues from peripheral infection. Brains were divided by dissection 144 
into brain stem, cerebellum, olfactory bulb, grey matter (cerebral cortex) and subcortex (corpus 145 
callosum, hippocampus, thalamus, and hypothalamus). Plaque assays were performed as 146 
previously described with Vero cells (38). Levels of WNV RNA in serum were measured by 147 
quantitative reverse transcription-PCR (qRT-PCR) as described (38, 40). 148 
 Generation and infection of primary cell cultures. All primary cell culture preparation 149 
and virus infection studies were performed as described below. In some experiments, cells were 150 
pretreated with indicated doses of mouse IFN-β prior to infection. 151 
(a) Murine embryonic fibroblasts. Murine embryonic fibroblasts (MEFs) were 152 
generated from embryonic day 14 WT and Ifi27l2a-/- mice. Embryos were decapitated, livers 153 
were removed and remaining minced tissue was digested in 0.25% (w/v) trypsin for 10 min at 154 
37˚C with periodic, gentle agitation and mechanical disassociation. Following trypsin 155 
neutralization with FBS, cells were cultured in DMEM supplemented with 20% HI-FBS, 1% 156 
HEPES, 1% Glutamax (Life Technologies), 100 U/ml penicillin and streptomycin (Gibco) and 1% 157 
non-essential amino acids (Gibco). Cells were infected at a multiplicity of infection (MOI) of 0.01. 158 
A subset of cells was pretreated with 5 U/ml of mouse IFN-β (E. coli-derived, PBL Assay 159 
Science) for 12 h prior to infection with WNV.  160 
(b) Macrophages and dendritic cells. Mφ and dendritic cells (DCs) were generated as 161 
previously described (41) from bone marrow of WT or Ifi27l2a-/- mice. Mφ and DCs were 162 
stimulated in culture for 8 days with either 40 ng/ml recombinant murine M-CSF (Peprotech) or 163 
20 ng/ml recombinant murine IL-4 and recombinant murine GM-CSF (Peprotech), respectively. 164 
Mφ and DCs were infected with WNV-NY at an MOI of 0.01 and 0.001, respectively.  165 
(c) Cortical neurons. CN were prepared from the cerebral cortex of embryonic day 15 166 
WT and Ifi27l2a-/- mice as described (42). Tissues were dissociated at 37˚C in 1 ml 0.25% (w/v) 167 
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trypsin, 0.25 mg DNase I (Sigma) in HBSS for 20 min. Trypsin was neutralized with 10% HI-FBS 168 
in DMEM and cells were filtered through a 70 μm filter and seeded at 5 x 105 cells/well on poly-169 
D lysine and laminin (10 μg/ml)-coated 24-well cell-culture treated plates. CN cells were cultured 170 
in Neurobasal medium (Life Technologies) supplemented with 2% B-27 (Gibco), 1% Glutamax 171 
and 100 U/ml penicillin and streptomycin.  172 
(d) Granule cell neurons. GCN were prepared from the cerebellum of 7 day-old pups 173 
and dissociated using the same protocol as for CN. These cells were cultured in the same 174 
medium as CNs with the addition of 40 mM KCl. Medium changes (50% of starting volume) 175 
were performed every 2 to 3 days, and neurons were maintained for 21 days in culture. In some 176 
experiments, neurons were pretreated for 24 h with 100 U/ml of IFN-β. Neurons were infected 177 
for 1.5 h at 37˚C, rinsed with HBSS twice and cultured in their respective complete neuronal 178 
medium. GCN were infected with WNV-NY or WNV-MAD at an MOI of 0.01 or 0.1, respectively. 179 
In some experiments, GCN were pretreated with IFN-β (150 or 100 IU/ml, for WNV-NY or WNV-180 
MAD, respectively) for 24 h. Viral titer was determined by focus-forming assay, as previously 181 
described (43).  182 
The purity of cultured neuron populations was defined by immunofluorescence 183 
microscopy analysis after incubating with antibodies to S100-β (1:200 dilution, Abcam 52642), 184 
NeuN (1:100 dilution, Milipore MAB377B), or IbaI (1:500 dilution, WAKO 019-19741) to identify 185 
astrocytes, neurons or microglia, respectively. Secondary Alexa fluor conjugated dyes 488 or 186 
555 were used (1:400 dilution, Invitrogen) for detection. Samples were imaged with a Nuance 187 
FX multiplex biomarker imaging system (Perkin Elmer). Using this analysis, our GCN cultures 188 
were comprised of 85% neurons and 12% astrocytes. 189 
 Cytokine and chemokine profiling. Cytokines and chemokines were profiled from 190 
serum at days 4 and 6 after peripheral WNV-NY infection. Protein levels were assayed with Bio-191 
Plex Pro Cytokine Assay per the manufacturer’s protocol.   192 
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 Immune cell analysis. Splenocytes and peripheral blood mononuclear cells were 193 
harvested from WT and Ifi27l2a-/- mice at day 8 after subcutaneous infection with WNV. Cells 194 
were stained for the following surface antigens following a 10 min preincubation with Fc-block 195 
(1:25 dilution; eBioscience): CD3 (1:25 dilution; BD Horizon, 500A2), CD4 (1:100 dilution; 196 
BioLegend, RM4-5), CD8α (1:100 dilution; Biolegend, 53-6.7), and CD19 (1:100 dilution; 197 
BioLegend, 6D5). Dead cells were excluded from analysis using Viability Dye eFluor (1:300 198 
dilution; eBioscience). Cells were washed, fixed, permeabilized and stained for granzyme B 199 
(1:50 dilution; Invitrogen, GB11) and the APC-conjugated Db-restricted NS4B peptide 200 
(SSVWNATTAI) tetramer (1:300 dilution, NIH Tetramer Facility (Atlanta, GA)). Blood monocytes 201 
were detected after staining with Gr-1 (1:100 dilution; BioLegend, RB6-8C5), CD115 (1:100 202 
dilution; eBioscience AFS98), CD8α (1:100 dilution), and F4/80 (1:100 dilution; Serotec, CI:A3-203 
1) antibodies. CD8- CD115+ F4/80+ cells were designated as monocytes after extensive gating 204 
analysis (44). The monocytes in blood include circulating CD115+ F4/80+ Gr-1lo monocytes that 205 
likely do not become resident within tissues. Circulating CD115+ F4/80+ Gr-1hi monocytes may 206 
enter tissue during inflammation (“inflammatory monocytes”) and differentiate into macrophages 207 
(44-47). All samples were processed on a LSR Fortessa and data were analyzed by FlowJo 208 
software (Tree-Star).     209 
  CNS leukocytes were isolated according to a published method (48). Briefly, eight days 210 
following subcutaneous WNV infection, mice were perfused extensively with PBS. Brain tissue 211 
was minced, and digested in HBSS supplemented with 0.05% collagenase D (Sigma), 0.1 μg/ml 212 
trypsin inhibitor TLCK (N-α-p-tosyl-L-lysine chloromethyl ketone), 10 μg/ml DNase I (Sigma), 213 
and 10 mM HEPES, pH 7.3 for 30 min. CNS cells were strained with a 70 μm filter and 214 
subjected to Percoll gradient (30% v/v) purification (1,200 x g, 30 min). Cells were washed, 215 
incubated with Fc-block, and stained for CD8α (1:100 dilution), CD11b (1:100 dilution), CD19 216 
(1:100 dilution), CD45 (1:100 dilution), Viability Dye eFluor (1:300 dilution) for 1 h at 4˚C, then 217 
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rinsed, and incubated with commercial cell fixative (eBioscience). Samples were processed on 218 
an LSR Fortessa flow cytometer and analyzed with FlowJo commercial software (Tree-Star). 219 
Neutrophils (CD11bhigh CD45high) were identified by their unique high side scatter profile. 220 
Mφ (CD11bhigh CD45high) and microglial (CD11bhigh CD45low) populations were identified by their 221 
relative expression of CD11b and C45 and their low to medium side scatter profiles.  222 
 The TFH and germinal center B cell responses were measured in the draining lymph 223 
node (DLN) 8 days post infection with WNV-NY. Cells were stained as previously described with 224 
fluorochrome or biotin-conjugated antibodies purchased from BD Biosciences, Biolegend, and 225 
eBioscience: CD3ε (145-2C11), CD4 (RM4-5), CD19 (1D3), PD1 (29F.1A12), FAS (Jo2), GL7 226 
and CXCR5 (2G8) (49).   227 
 Serum antibody analysis. WNV-specific IgG and IgM dilution endpoint titers were 228 
determined by ELISA against purified WNV E protein, as previously described (50). Focus 229 
reduction neutralization (FRNT50) assays were performed as previously described on Vero cells 230 
following serial dilution of serum with 100 FFU of WNV (39, 49). 231 
 TUNEL staining. Brain tissue was harvested from mice nine days after subcutaneous 232 
WNV infection. Mice were perfused with 30 ml PBS and half of the brain was retained for viral 233 
titer analysis, while the other brain half was fixed in 4% paraformaldehyde (PFA) in PBS 234 
overnight. This was followed by a 6 h incubation of brains in 20% sucrose solution and overnight 235 
incubation in 30% sucrose solution, all at 4˚C. Selected brains (from WT or Ifi27l2a-/- mice) with 236 
equivalent viral titers (1 to 8 x 105 PFU/g) were embedded in Optimal Cutting Temperature 237 
medium (OTC; Tissue-Tek), frozen at -80oC, and sectioned in 10 μm slices on a Microm 238 
HM505N Cryostat on positively charged slides (Globe Scientific, 1358W). TUNEL staining was 239 
performed with the Roche In Situ Cell Death Detection Kit-TMR red per the manufacturer’s 240 
instructions. Neurons were co-stained with anti-NeuN (1:100 dilution; Millipore, A60), secondary 241 
Alexa Fluor 488 (1:400 dilution) and nuclei were visualized with DAPI. Slides were mounted with 242 
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Prolong Gold Diamond anti-fade mounting media (Invitrogen). Tissues were imaged on a Zeiss 243 
LSM880, AxioObserver confocal microscope at the Washington University Microscopy Core 244 
Facility, with a Plan-Apochromat 40x/1.4 oil DIC M27 objective. DAPI, Alexa Fluor 488, and 245 
TMR-red were detected with the respected wavelength channels: 415-470, 491-553, and 553-246 
624. The image, approximately 637.64 μm x 637.64 μm, was comprised by automated tiling of 9 247 
panels (Zeiss Zen), with the central panel being selected for TUNEL positive cells in the same 248 
region of the brain tissue in each animal.  Four mice were imaged per genotype with two tissue 249 
slices per mouse and two images per tissue slice for both brain stem and cerebellum. TUNEL 250 
positive events were counted within the 9-tiled composite image. 251 
qRT-PCR assays. WNV, Oas1a and Ifit1 mRNA was analyzed from RNA extracted from 252 
GCN following treatment with either IFN-β (100 U/ml), poly(I:C) (50μg/ml) (InvivoGen), WNV-NY 253 
(MOI, 5) or WNV-MAD (MOI, 5) for 8 h prior to collection in lysis buffer. qRT-PCR was 254 
performed as previously described for WNV, Oas1a and Ifit1 and gene expression was 255 
normalized to Gapdh (51). Commercially available Ifi27l2a primer-probe assay was purchased 256 
from IDT. TaqMan RNA-to-CT 1-Step Kit was used for qRT-PCR.   257 
Blood-brain barrier permeability. Blood-brain barrier (BBB) studies were performed as 258 
previously described (52). Briefly, 4 days after subcutaneous infection with WNV-NY, WT and 259 
Ifi27l2a-/- mice were injected via an intraperitoneal route with 100 μl of a 100 mg/ml fluorescein 260 
(Sigma) in PBS. Dye was allowed to circulate for 45 min, serum was collected as a 261 
normalization control, mice were perfused with 20 ml PBS, and brain regions were collected for 262 
analysis as previously described (52).  263 
 Statistical analyses. All data were analyzed with Prism software (GraphPad Prism, San 264 
Diego, CA). qRT-PCR with more than two comparisons between groups was analyzed by one-265 
way ANOVA with Tukey’s HSD post hoc analysis. qRT-PCR data with two group comparisons 266 
was analyzed by Student’s t-test with correction for multiple comparisons Holm-Sidak method. 267 
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Serum cytokine levels were analyzed by Student’s t-test with correction for multiple 268 
comparisons Holm-Sidak method. Kaplan-Meier survival curves were analyzed by the Mantel-269 
Cox Log-rank test. Viral burden in tissues was analyzed by the Mann-Whitney test. Serum 270 
antibody titers were analyzed by Student’s t-test. For viral growth kinetics in cell culture, the log 271 
transformed viral titer was analyzed by Student’s t-test. Flow cytometry based assays, where 272 
total cell count or percent total cell count was measured, also was analyzed by a Student’s t-273 




 A deficiency of Ifi27l2a increases susceptibility to WNV infection. The ISG Ifi27l2a 277 
is differentially upregulated in selected neurons of the brain after WNV infection, and ectopic 278 
expression of Ifi27l2a in cultured cortical neurons inhibited infection by WNV (14). To explore an 279 
antiviral role in vivo for this relatively poorly characterized ISG, we generated Ifi27l2a-/- mice 280 
using a targeted gene deletion strategy (Fig 1A); deletion of Ifi27l2a was validated by PCR (Fig 281 
1B). In WT mice, basal Ifi27l2a mRNA expression was observed in lymph node, heart, lung and 282 
testes, and to a lesser extent in the kidney and spleen. Following WNV infection, Ifi27l2a mRNA 283 
expression was induced in the brain and spinal cord (Fig 1C). To quantify Ifi27l2a mRNA 284 
expression in response to viral infection, we analyzed selected tissues at successive time points 285 
following peripheral inoculation (Fig 1D). At 4 and 8 days post infection, Ifi27l2a mRNA 286 
expression was enhanced in the brain (2.0- and 3.3-fold, respectively; P < 0.005) and the spinal 287 
cord (2.1- and 2.0-fold, respectively; P < 0.005). Within the spleen, higher levels of Ifi27l2a 288 
mRNA were observed 4 days after infection (12-fold, P < 0.05). We also analyzed Ifi27l2a-/- and 289 
wild-type (WT) mice for possible differences in immune cells subsets in the spleen and blood. 290 
Although the numbers of CD4+ and CD8+ T cells and CD19+ B cells were similar, Ifi27l2a-/- mice 291 
had slightly greater numbers of splenic NK cells (NK1.1+) than WT mice (Table 1); while 292 
noteworthy, this phenotype may less important in the context of WNV infection, as NK cell 293 
depletion does not impact WNV pathogenesis in mice (53, 54). Within the peripheral blood 294 
leukocyte compartment, we observed similar numbers of myeloid cells, monocytes, and subsets 295 
of granulocytes (Table 2). 296 
 We next infected WT and Ifi27l2a-/- congenic mice with a pathogenic isolate of WNV 297 
(strain 3000.0259, WNV-NY). After subcutaneous infection with 102 PFU of WNV-NY, Ifi27l2a-/- 298 
mice exhibited a decreased survival rate compared to WT animals (29% versus 63%, P < 0.05) 299 
although the mean time to death was similar between the two groups (Fig 2A).  300 
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 WNV burden in the CNS of Ifi27l2a-/- mice. To understand why an absence of Ifi27l2a 301 
resulted in enhanced pathogenicity of WNV-NY, viral burden was examined at different days (2, 302 
4, 6, 8, 10, or 14) in serum, peripheral organs (spleen and kidney), and CNS tissues (brain and 303 
spinal cord). WNV viremia at days 2, 4, and 6 was similar between WT and Ifi27l2a-/- mice (Fig 304 
2B). At all time points tested, viral burden in the spleen also was similar between WT and 305 
Ifi27l2a-/- mice (Fig 2C). Moreover, a deficiency in Ifi27l2a did not result in productive infection of 306 
the kidney (Fig 2D), an organ that is typically resistant to WNV-NY infection in WT mice yet 307 
permissive in animals with defects in type I IFN induction, signaling, or effector functions (55-308 
59). However, within the CNS at day 8 after infection, WNV-NY burden increased in the brain 309 
(2.4-fold, P < 0.05) and spinal cord (170-fold increase, P < 0.005) of Ifi27l2a-/- mice (Fig 2E and 310 
F). This difference in viral titer was not apparent at later time points, and by day 14, infectious 311 
virus was not detectable within the CNS or peripheral tissues in surviving animals from both 312 
genotypes, suggesting that Ifi27l2a-/- animals did not have a defect in the clearance phase of 313 
WNV, which requires CD8+ effector T cells (36).      314 
 To corroborate these findings, we performed plaque assays on tissue homogenates 315 
isolated from specific regions of the CNS. WT and Ifi27l2a−/− mice were infected with WNV-NY 316 
via a subcutaneous route and viral burden in the brain stem, cerebellum, cerebral cortex, sub-317 
cortex (defined in Methods), and olfactory bulb was measured at day 8 after infection (Fig 2G-318 
K). Although we observed no differences in WNV titers in the cerebral cortex, sub-cortex, or 319 
olfactory bulb, higher levels of infection were observed in the cerebellum and brain stem (590-320 
fold, P < 0.05; 5,200-fold, P < 0.05, respectively) from Ifi27l2a−/− mice. These data suggest that 321 
Ifi27l2a has a protective, antiviral role in selected regions of the CNS. 322 
WNV infection after direct intracranial inoculation. As Ifi27l2a-/- mice exhibited higher 323 
viral titers in the brain stem and cerebellum, we postulated that Ifi27l2a might protect specific 324 
regions when virus was administered directly into the CNS. Unexpectedly, following intracranial 325 
inoculation of WNV-NY into the cerebral cortex, we observed no differences in viral titers within 326 
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different regions of the CNS at either 3 or 5 days after infection (Fig 3A-F). Because WNV-NY 327 
strain is highly virulent, we repeated intracranial infection studies with the attenuated WNV 328 
Madagascar strain (WNV-MAD), which is more sensitive to the antiviral effects of type I IFN (14, 329 
37, 60). We observed a modest, (17-fold, P < 0.05) yet statistically significant phenotype, with 330 
greater WNV-MAD infection at day 3 after infection in the brain stem of Ifi27l2a-/- mice (Fig 3G-331 
L). Thus, Ifi27l2a had an antiviral effect when virus was introduced directly into the CNS, 332 
although its magnitude was limited and only apparent with an attenuated, more IFN-sensitive 333 
strain.  334 
Ifi27l2a does not alter cellular or humoral immune responses during acute WNV 335 
infection. As depressed antiviral CD8+ T cell or antibody responses can facilitate dissemination 336 
to and replication of WNV within the CNS (reviewed in, 12), we investigated whether an 337 
absence of Ifi27l2a influenced the development of cellular and adaptive immunity during WNV-338 
NY infection. Initially, we examined the effects of Ifi27l2a on lymphocyte numbers in the 339 
peripheral tissues. At baseline, normal numbers and percentages of B cells, CD4+ T cells, and 340 
CD8+ T cells were present in the blood and spleen. Because a previous study suggested that 341 
Ifi27l2a modulates inflammation, possibly through regulation of Mφ differentiation (24, 35), we 342 
profiled monocytes in blood during WNV infection (Fig 4A). At day 8 after infection, Ifi27l2a-/- 343 
and WT mice had similar percentages and numbers of circulating and inflammatory blood 344 
monocytes based on differential expression of the surface markers F4/80, CD115, and Gr-1 345 
(Ly6C and Ly6G) (Fig 4B-C and Methods).  346 
We next evaluated T cell responses in peripheral organs by characterizing the relative 347 
levels of CD4+ and CD8+ T cells (Fig 5A). At day 8 after WNV-NY infection, equivalent 348 
percentages and numbers of CD4+ and CD8+ cells were observed in the spleen (Fig 5B-C). 349 
Furthermore, no difference in granzyme B+ NS4B tetramer+ antigen-specific CD8+ T cells was 350 
observed in the spleens of WT and Ifi27l2a-/- mice. We assessed whether leukocyte 351 
accumulation in the CNS was altered, which independently could affect disease outcome. 352 
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Leukocytes were isolated from brains of WT and Ifi27l2a-/- mice at day 8 and analyzed by flow 353 
cytometry (Fig 5D). We observed similar percentages and numbers of CD4+ and CD8+ T cells or 354 
granzyme B+ NS4B tetramer+ CD8+ T cells within the brain (Fig 5E-F). Microglia and infiltrating 355 
Mφ were characterized by CD45 and CD11b surface expression (Fig 5G). We also observed no 356 
differences in the percentage or numbers of activated microglia (CD11bhigh CD45low) or Mφ 357 
(CD11bhigh CD45high) (Fig 5H-I) in the brains of WT and Ifi27l2a-/- mice after WNV-NY infection. 358 
Thus, a deficiency of Ifi27l2a did not affect priming, the recruitment, or activation of antigen-359 
specific or innate immune cells in the CNS of WNV-infected mice. 360 
 To assess the effect of Ifi27l2a on WNV-specific antibody responses, we analyzed 361 
serum from Ifi27l2a-/- and WT mice on day 8 after infection for binding to the WNV E protein. We 362 
observed elevated IgG titers (3.2-fold, P < 0.0005) in Ifi27l2a-/- mice compared to WT mice (Fig 363 
6A), but no difference in IgM titers (Fig 6B). However, neutralization assays detected no 364 
difference in the ability of serum-derived antibody from WT and Ifi27l2a-/- mice to neutralize 365 
WNV-NY infection (Fig 6C). 366 
 Because of the increased IgG titers in Ifi27l2a-/- mice, we next characterized whether 367 
there were differences in the T cell-dependent germinal center response in DLN of WNV-NY 368 
infected mice at 8 days post infection. T follicular helper cells were characterized as CD4+, 369 
PD1+, and CXCR5+ (TFH, Fig 6D) and germinal center B cells were classified as CD19+, Fas+, 370 
and GL7+ (GC B, Fig 6E). As the total numbers and percentages of TFH and GC B cells were 371 
similar in WNV-infected WT and Ifi27l2a-/- mice, a deficiency in Ifi27l2a did not appear to alter 372 
the germinal center response within the DLN. 373 
 Cytokine and chemokine expression profiles in serum of WNV-infected Ifi27l2a-/- 374 
mice. Because specific vasoactive cytokines (e.g., TNF-α, IL-1β, and IL-6) can alter the blood-375 
brain barrier (BBB) and affect transit of WNV into the brain parenchyma and early replication 376 
(reviewed in 10, 11), we measured whether a deficiency of Ifi27l2a affected systemic production 377 
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of cytokines and chemokines at 4 or 6 days after WNV-NY infection. In WNV infected mice, we 378 
observed greater expression of IL-1β and eotaxin in WT mice compared to Ifi27l2a-/- at 4 days 379 
after infection (3.0-fold, P < 0.05; 1.2-fold, P < 0.05), but not other cytokines and chemokines 380 
(Table 3). Consistent with this small variation in cytokine expression in serum, we did not 381 
observe differences in blood-brain barrier permeability between WT and Ifi27l2a-/- mice (data not 382 
shown). To assess whether this small variation in cytokine expression in serum impacted BBB 383 
permeability and possibly virus entry into the CNS, we injected the small molecule sodium 384 
fluorescein via an intraperitoneal route into WT and Ifi27l2a-/- at 4 days after WNV infection and 385 
then measured extravasation into different regions of the CNS. Notably, similar levels of sodium 386 
fluorescein accumulated in the cerebral cortex, cerebellum, brain stem, and spinal cord (data 387 
not shown). Thus, the small increases in serum cytokine levels in the absence of Ifi27l2a did not 388 
substantively impact BBB permeability.  389 
Ifi27l2a exhibits antiviral effects against WNV in Mφ but not DCs or MEFs. Although 390 
Ifi27l2a is expressed after WNV infection in primary and secondary lymphoid tissues, we did not 391 
observe greater viral burden in peripheral organs. We speculated that the antiviral effect of 392 
Ifi27l2a against WNV infection might not occur in non-neuronal cell types. To evaluate this 393 
hypothesis, we generated bone marrow-derived Mφ and DCs and primary MEFs from WT and 394 
Ifi27l2a-/- mice. Cells were either pretreated with IFN-β or not treated and were then 395 
subsequently infected at a low MOI with WNV-NY. We observed increased WNV-NY replication 396 
in untreated or IFN-β treated Mφ at later time points (P < 0.05, Fig 7A). However, we observed 397 
no difference in viral infection at any time point in DC or MEF cultures generated from WT and 398 
Ifi27l2a-/- mice (Fig 7B-C).  399 
 Subsets of primary neurons from Ifi27l2a-/- mice exhibit enhanced WNV infection. 400 
Given that the virologic phenotype occurred in selected brain regions of Ifi27l2a-/- mice, we 401 
investigated whether Ifi27l2a had differential antiviral activity in different neuron populations. We 402 
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prepared primary neurons from the cerebral cortex (CN) and cerebellum (GCN) of WT and 403 
Ifi27l2a-/- mice, pretreated select cells with IFN-β, and measured viral growth kinetics after 404 
infection with WNV-NY. We detected no differences in replication kinetics in CN, with only mild 405 
suppression of infection with IFN-β pretreatment (Fig 8A), as seen previously (14). Somewhat 406 
unexpectedly, we observed similar viral growth kinetics in GCN from WT and Ifi27l2a-/- mice for 407 
WNV-NY, with replication being suppressed to a greater degree following IFN-β pretreatment 408 
(Fig 8B), also as reported previously (14). We reassessed viral growth kinetics with the more 409 
IFN-sensitive strain, WNV-MAD. Ifi27l2a-/- GCN supported higher levels of WNV-MAD infection 410 
and this effect was more pronounced when cells were pretreated with IFN-β (18-fold, P < 0.05, 411 
Fig 8C) and a difference in viral replication was present in non-IFN-β treated cells (55-fold). 412 
Consistent with this data, by 72 hours after infection, a greater proportion of WNV-MAD infected 413 
GCN was observed in Ifi27l2a-/- versus WT GCN (Fig 8D). Because we observed differences in 414 
WNV restriction in WT and Ifi27l2a-/- GCN, we considered whether a deficiency of Ifi27l2a 415 
altered the general ISG response in GCN. We treated cells with known ISG inducers (IFN-β, 416 
Poly(I:C), WNV-NY and WNV-MAD) and assessed expression of Oas1a and Ifit1 mRNA. As 417 
Oas1a and Ifit1 induction was similar in WT and Ifi27l2a-/- GCN (Fig 8E-F), a deficiency of 418 
Ifi27l2a did not broadly impact expression of other antiviral ISGs.   419 
Ifi27l2a-/- mice exhibit less neuronal death in the cerebellum and brain stem after 420 
WNV infection. To provide a mechanistic link between our in vitro and in vivo phenotypes with 421 
Ifi27l2a-/- cells and mice, we prepared brain tissue sections for histological and 422 
immunohistochemical analyses. Although historically we have detected WNV antigen staining in 423 
neurons of different brain regions at day 9 after infection in younger (e.g., 5 and 8 week-old 424 
mice) (61, 62), despite multiple attempts, the viral antigen staining in 11 to 12 week-old WT or 425 
Ifi27l2a-/- mice was inconclusive. The levels of viral antigen in the CNS were at the threshold of 426 
detection, with only sporadic staining of infected neurons in different brain regions of a subset of 427 
the mice (data not shown). Because of this, and prior reports suggesting that some Ifi27 family 428 
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members (e,g., ISG12a) were required for IFN-induced cellular apoptosis (21, 31, 32), we 429 
evaluated neuronal cell death in WT and Ifi27l2a-/- mice that had equivalent WNV titers in the 430 
brain at 9 days after infection. We noted significantly more cell death in the cerebellum (5-fold, P 431 
< 0.05) (Fig 9A and C) and brain stem (4-fold, P < 0.005) (Fig 9B and C) of WT mice, whereas 432 
TUNEL positive neurons were largely absent in the hindbrain regions of Ifi27l2a-/- mice. 433 
  434 
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DISCUSSION 435 
 Viral replication and the subsequent immune response within the CNS can result in 436 
significant morbidity and mortality. Because neurons are largely non-renewable, it is imperative 437 
that the host clears viral infection while protecting cells from direct or collateral immune-438 
mediated damage. We previously identified Ifi27l2a as a putative inhibitory ISG that was 439 
expressed preferentially within neurons of the cerebellum compared to those from the cerebral 440 
cortex (14). Here, we established a protective antiviral role for Ifi27l2a in vivo against WNV. 441 
Ifi27l2a-/- mice were more susceptible to WNV-induced mortality, and sustained higher viral titers 442 
in the cerebellum, brain stem, and spinal cord. Remarkably, at day 9 after infection, Ifi27l2a-/- 443 
mice had less cell death in neurons of the cerebellum and brain stem. Ifi27l2a-/- mice showed no 444 
apparent defects in their ability to generate peripheral or CNS cellular immune response, and 445 
WNV replication was equivalent in several other cell types that lacked or expressed Ifi27l2a.  446 
Several members of the Ifi27 family have been studied in the context of viral infections. 447 
Many viruses induce expression of Ifi27 family members, including influenza A virus, Sindbis 448 
virus, WNV, JEV, and human immunodeficiency virus-1 (14, 63-66). Our prior study reported 449 
that ectopic expression of Ifi27l2a in CN reduced WNV infection whereas siRNA mediated gene 450 
silencing in GCN resulted in enhanced viral replication (14). Work by others has shown that 451 
ectopic expression of human IFI27 (ISG12A) inhibited replication of HCV in Huh-7.5 cells, and 452 
reciprocally siRNA mediated silencing of human IFI27 enhanced HCV replication (67). High 453 
levels of expression of human IFI27 also inhibited Newcastle Disease virus (NDV) replication 454 
and oncolytic activity in Huh7 cells (34).   455 
Ifi27l2a-/- mice have been investigated in other contexts. Although Ifi27l2a was identified as 456 
an upregulated ISG in lung tissue following influenza virus infection (65), Ifi272la-/- C57BL/6 mice 457 
did not sustain higher viral burden or altered pathology in the lungs of infected animals (33). In 458 
another Ifi27l2a-/- mouse of mixed genetic background, gene-deficient animals were protected 459 
against caecal ligation induced-sepsis, LPS endotoxemia, or vascular injury after arterial ligation 460 
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(24, 35). In contrast, our Ifi27l2a-/- C57BL/6 mice succumbed to LPS administration at a rate 461 
similar to WT mice (T. Lucas and M. Diamond, unpublished observations). Although Ifi27l2a has 462 
a postulated role in regulating inflammation, at least in the context of WNV infection, we failed to 463 
observe hypercytokinemia, changes in the infiltrating immune cells, or altered adaptive immunity 464 
in Ifi27l2a-/- mice.  465 
The unique cell-type expression, sub-cellular localization, and induction patterns of Ifi27 466 
family genes suggest possible modular functions. Humans have four IFI27 members, of which 467 
only IFI27 and IFI6-16 (IFI6) are IFN-inducible. Mice have three gene paralogs, Ifi27 (Ifi27l1), 468 
Ifi27l2a, and Ifi27l2b, all of which are IFN-inducible, with Ifi27l2a exhibiting the greatest induction 469 
after type I IFN treatment (19). IFI27 family members have been suggested to localize to the 470 
mitochondria (21, 22) or to the nuclear membrane (23, 24); in the latter case, IFI27 interacts 471 
with and sequesters the nuclear receptor NR4A1, which regulates expression of anti-472 
inflammatory genes (24). IFI27 family members also appear to have pro-apoptotic effects (21, 473 
32, 34, 68, 69), possibly through stabilization of the mitochondrial membrane and regulation of 474 
caspase activity (21, 68). Perhaps because of these proposed pleotropic activities, IFI27 family 475 
members have been associated with over-expression in certain cancers (69, 70), promotion of 476 
skin keratinocyte replication (71), and DNA-damage induced apoptosis and cytochrome c 477 
release (21). IFI6-16 (IFI6) is an ISG12-motif containing family member that may share some 478 
functions with Ifi27l2a. In the context of DENV infection, a deficiency of IFI6-16 was associated 479 
with increased caspase levels and decreased Bcl-2 expression and mitochondrial membrane 480 
stabilization (68). Additionally, ectopic expression of IFI6-16 has been shown to suppress 481 
infection of YFV virus (72). Our in vivo data is most consistent with a model in which Ifi27l2a is 482 
induced by type I IFN in response after WNV infection, and in a cell-type specific manner (for 483 
reasons that still remain uncertain), promotes cell death. In its absence (Ifi27l2a-/- mice), subsets 484 
of virally infected neurons (e.g., in the cerebellum, brain stem, and possibly spinal cord) live 485 
longer, which allows greater yields of virus to accumulate, at least during the early phase of 486 
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CNS infection. We speculate that the increased rate of death of WNV-infected Ifi27l2a-/- mice 487 
ultimately is caused by virus-induced injury of neurons in regions of the CNS that control key or 488 
autonomic function. Our study, along with the work of others, suggest multiple possible 489 
functions for different Ifi27 family members, with some of the antiviral properties being linked to 490 
cell death phenotypes in infected cells.  491 
The predominant effect of Ifi27l2a in the CNS suggests a specialization of the host antiviral 492 
immune response. Analogously, preferential antiviral roles in the CNS for other ISGs (Ifit2 and 493 
Rsad2 (viperin)) have been reported. In Ifit2-/- mice, higher WNV and VSV titers were observed 494 
in the olfactory bulb, brain stem, and cerebellum (13, 73). In Rsad2-/- mice, an increase in WNV 495 
infection was observed in the cerebral cortex, white matter, and spinal cord (55). We observed 496 
differences in the regional restriction of WNV in the CNS mostly in the context of peripheral viral 497 
but not intracranial infection, with the exception of the brain stem. Viral infection of peripheral 498 
immune tissues (e.g., lymph node or spleen) may induce systemic accumulation of type I IFN 499 
that primes the antiviral response in the brain either earlier or prior to viral entry into the CNS, 500 
whereas direct administration of virus to the CNS may permit rapid replication of WNV in 501 
neurons in the context of a less robust type I IFN response. Although future studies are needed 502 
to determine why region-specific antiviral effects of individual ISGs occur, we speculate that 503 
these genes do not function in isolation, and partner proteins that are expressed differentially 504 
may regulate their activity. While our findings suggest an antiviral function within select neurons 505 
and Mφ, the precise cellular mechanism of action of Ifi27l2a warrants further investigation. 506 
In summary, we have identified a protective role for Ifi27l2a in the CNS following WNV 507 
infection. Ifi27l2a mediated restriction of WNV was greatest in the cerebellum, brain stem and 508 
spinal cord, and correlated with an antiviral and cell survival effect in subsets of neurons and 509 
myeloid cells. These findings suggest that Ifi27l2a may have a discrete antiviral activity within 510 
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FIGURE LEGENDS 524 
Figure 1. Generation of Ifi27l2a-/- mice and tissue expression of Ifi27l2a. Scheme of 525 
Ifi27l2a locus with targeting cassette (A). Exons are noted in grey and target location is noted 526 
with black arrow. Ifi27l2a gene deletion was verified by PCR. Genotyping was verified with a 527 
positive control plasmid containing wild-type Ifi27l2a and negative controls with a null plasmid 528 
control. Ifi27l2a deletion was confirmed by the presence of 408 bp band, whereas WT Ifi27l2a 529 
manifests as a 612 bp band (B). The Ifi27l2a RT-PCR product was screened for in brain, spinal 530 
cord, lymph node (LN), spleen, kidney, lung, liver, white fat, and testes (C). Selected mice were 531 
infected subcutaneously with WNV-NY and tissues were collected 4 days after infection and 532 
compared to mock-infected animals. The results are representative of 2 to 3 mice per treatment 533 
group. Following peripheral infection by WNV-NY, selected tissues were collected at 4 and 8 534 
days after infection and expression of Ifi27l2a mRNA was compared to mock infected animals 535 
(D). Ifi27l2a mRNA was measured in brain, spinal cord, spleen, and lymph node, and 536 
normalized to Gapdh by qRT-PCR. Means were compared between mock and infected groups 537 
using one-way ANOVA followed by Tukey’s HSD Post Hoc analysis (*, P < 0.05, **, P < 0.005). 538 
Bars are mean + SEM. 539 
 Figure 2. Survival and viral burden analysis for WT and Ifi27l2a-/- mice infected 540 
with WNV. (A) Survival analysis of 11 to 12 week-old WT or Ifi27l2a-/- mice after inoculation with 541 
102 PFU of WNV-NY by subcutaneous injection in the footpad. In (A) WT (n = 39) and Ifi27l2a-/- 542 
(n = 34) mice were used for survival curves. Asterisks indicate differences that were statistically 543 
significant compared to WT mice (Mantel-Cox log rank test analysis; P < 0.05). Viral burden 544 
after WNV-NY infection of WT or Ifi27l2a-/- mice was measured by qRT-PCR (B) or plaque 545 
assay (C-G) in samples from serum (B), Spleen (C), kidney (D), brain (E), and spinal cord (F) at 546 
the indicated time points after infection. (G-K) Selected brain regions were assayed for viral 547 
burden at 8 days post subcutaneous infection with WNV-NY. Data points represent individual 548 
mice. Bars indicate median values and were obtained from 16 to 17 mice per tissue. Asterisks 549 
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indicate statistical significance as determined by the Mann-Whitney test (*, P < 0.05, **, P < 550 
0.005). Dotted line indicates the limit of detection for each tissue. Data are pooled from at least 551 
three independent experiments. 552 
 Figure 3. Viral titers in the brain after intracranial infection of WT and Ifi27l2a-/- 553 
mice. Mice were infected with either 101 PFU WNV-NY (A-F) or WNV-MAD (G-L) via an 554 
intracranial route and selected CNS regions were harvested and viral burden was determined 555 
by plaque assay. Data points represent individual mice. Bars indicate median values and were 556 
obtained from 4 to 10 mice per time point per tissue. Dotted lines represent the limit of detection 557 
of the assay. Asterisks indicate statistical significance as determined by the Mann-Whitney test 558 
(*, P < 0.05). 559 
 Figure 4. Circulating monocytes isolated from the blood of WT and Ifi27l2a-/- mice. 560 
Circulating blood monocytes were gated as CD8- F4/80+ CD115+ and analyzed for expression of 561 
additional surface markers including Gr-1 (Ly6C and Ly6G) (A). WT and Ifi27l2a-/- monocytes 562 
were present at similar levels at 8 days post infection in the blood. Specific monocyte 563 
populations of Gr-1high and Gr-1low cells were phenotyped according to prior studies (45, 74) and 564 
presented as either percent (B) or total number (C) of cells per ml of blood from WT and 565 
Ifi27l2a-/- mice. For each group, a Student’s t-test was used to compare cells from WT to 566 
Ifi27l2a-/- mice. Bars indicate mean values for 8 to 9 mice for each genotype from three 567 
independent experiments.  568 
Figure 5. Splenic T cell and brain-specific immune response to WNV infection in 569 
WT and Ifi27l2a-/- mice. (A) T cells were identified by inclusion of CD19- and CD3+ cells, and 570 
analyzed by CD4 and CD8. CD8+ cells were additionally analyzed as granzyme B+ and WNV-571 
specific NS4B tetramer+. At 8 days after subcutaneous infection with WNV-NY, splenocytes 572 
were harvested. Similar percentages (B) and absolute cell numbers (C) were observed for CD4+ 573 
T cells, CD8+ T cells or WNV specific granzyme B+ NS4B tetramer+ CD8+ T cell (n = 11). For 574 
each group, Student’s t-test was used to compare values from WT to Ifi27l2a-/- mice (P < 0.05). 575 
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Bars indicate mean values. Brain cells were purified by Percoll gradient centrifugation from 576 
brains of mice at 8 days post infection. (D) Cells were gated as CD8+ positive, and WNV-577 
specific CD8+ T cells were identified by co-staining for granzyme B and with WNV-specific 578 
NS4B tetramer. The percentages of CD4+ and CD8+ T cells, as well as NS4B-specific cells, 579 
were similar between WT and Ifi27l2a-/- mice (E). No difference in absolute number of infiltrating 580 
CD4+ and CD8+ T cells, or the WNV specificity of CD8+ T cells was observed (F). Brains were 581 
analyzed for numbers of macrophages (CD45high CD11b+) and microglia (CD45low and CD11b+) 582 
(G). The percentages and number (H-I) of macrophages and microglia were similar between 583 
WT and Ifi27l2a-/- mice. WT and Ifi27l2a-/- samples percentages and absolute numbers for three 584 
independent experiments were compared with a Student’s t-test (n = 7 to 11 mice, *, P < 0.05). 585 
Bars indicate mean values. Y-axes are cell-type dependent. 586 
 Figure 6. Antibody responses in WT and Ifi27l2a-/- mice after WNV infection. Serum 587 
was obtained from WNV-infected WT and Ifi27l2a-/- mice and IgG levels (A) or IgM levels (B) at 588 
8 days after infection and measured by ELISA for reactivity with WNV E protein. Neutralizing 589 
antibody titers were determined by a focus-reduction assay from serum at day 8 (C). Results 590 
are shown as a scatter plot and represent samples from 7 to 10 mice per group. Data are 591 
plotted as the log10 endpoint neutralization titer or log10 focus reduction neutralizing titer 50 592 
(FRNT50). A Student’s t-test was used to compare data from WT and Ifi27l2a-/- mice (***, P < 593 
0.0005). D-G. TFH cells (PD1+ and CXCR5+) (D) and GC B cells (Fas+ and GL7+) (E) populations 594 
were identified in the DLN at 8 days post WNV-NY infection. Total numbers of TFH cells and GC 595 
B cells (F) and percentages of TFH cells of total CD4+ cells and GC B cells of total CD19+ cells 596 
(G) were similar between WT and Ifi27l2a-/- mice. Bars indicate mean values. 597 
Figure 7. Ifi27l2a restricts WNV replication in Mφ, but not DC or MEFs. (A) Bone 598 
marrow derived Mφ were infected with WNV (MOI, 0.01) and viral replication kinetics were 599 
followed for 72 h. A subset of Mφ was pretreated with IFN-β (1 U/ml for 6 h) prior to infection. (B) 600 
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Bone marrow derived DCs were infected with WNV (MOI, 0.001) and viral kinetics were 601 
followed for 72 h. A subset of DCs was pretreated with IFN-β (10 U/ml for 6 h) prior to infection. 602 
(C) MEFs were infected with WNV (MOI, 0.01) and viral kinetics were followed for 72 h. A 603 
subset of MEFs was pretreated with IFN-β (10 U/ml for 6 h). The data analyzed by a Student’s t-604 
test for each time point, between each treatment group and is expressed as the log10 median 605 
titers + SEM as reflects pooled data from 3 to 4 independent experiments with three technical 606 
replicates per independent experiment for each cell type. Y-axes range is cell-type dependent. 607 
 Figure 8. Viral infection of WT and Ifi27l2a-/- primary neurons. Primary neuron 608 
cultures were generated from WT and Ifi27l2a-/- mice and infected with WNV-NY or WNV-MAD 609 
Cell supernatants were harvested at the indicated time points and titrated by focus forming 610 
assay. CN (A) and GCN (B-C) were infected at the following MOI: WNV-NY, 0.01; WNV-MAD, 611 
0.1. In some experiments, GCN and CN were pretreated with IFN-β for 24 h (CN: 150 U/ml for 612 
WNV-NY; GCN: 150 U/ml for WNV-NY or 100 U/ml WNV-MAD). (D) WT and Ifi27l2a-/- GCN 613 
were infected with WNV-MAD for 72 h and infected neurons (MAP2+) cells were counted by 614 
automated high throughput imaging. WT and Ifi27l2a-/- GCN were analyzed by qRT-PCR for 615 
expression of Oas1 (E) and Ifit1 (F). Viral replication data was analyzed at each time point, for 616 
each treatment by a Student’s t-test for each treatment group (*, P < 0.05, n = 3 to independent 617 
replicates). GCN infection assay results were analyzed by Student’s t-test (two experimental 618 
replicates, 3 to 4 samples wells per replicate) (*, P < 0.05). For high throughput imaging, three 619 
wells per treatment group were analyzed for each biological replicate (n = 3). For each well, 60 620 
computer-randomized images were collected and analyzed by GE IN Cell 2000 imager and IN 621 
Cell Software. qRT-PCR data was analyzed by a Student’s t-test with correction for multiple 622 
comparisons by Holm-Sidak method (*,P < 0.05). NT = Not treated. 623 
 Figure 9. Neuronal death within the cerebellum and brain stem of WNV infected 624 
mice. Nine days following subcutaneous infection with WNV-NY, brains of selected mice with 625 
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similar levels of virus were sectioned and stained for neurons (NeuN, green), cell death (as 626 
determined by TUNEL staining, red) and nuclei (DAPI, blue). Cerebellum (A) and brain stem (B) 627 
tissues were analyzed by confocal microscopy and fields of view containing TUNEL staining 628 
were quantitated for number of events per field of view (C) (n = 4 mice per genotype, 2 sections 629 
per mouse, 2 fields of view per section). The relative number of TUNEL+ cells in WT and 630 
Ifi27l2a-/- mice were analyzed by Student’s t-test, with bars indicating the means (*, P < 0.05; **, 631 
P < 0.005). Scale bars = 100 μm. Yellow arrows indicate examples TUNEL+ nuclei. 632 
  633 
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Table 1. Immunophenotyping of lymphocytes in the spleen of naive WT and Ifi27l2a-/- 634 
mice.  635 
   WT Ifi27l2a-/- 
   Absolute Percent Absolute Percent 
Subset AVG +SD AVG +SD AVG +SD AVG +SD 
CD4+ - 2.84E+08 4.74E+07 14.20 1.78 2.95E+08 2.72E+07 14.13 1.08 
CD44high CD62llow 3.05E+07 2.26E+06 10.88 1.08 3.52E+07 8.57E+06 11.93 2.85 
CD44low CD62lhigh 2.10E+08 2.14E+08 73.60 2.68 4.22E+07 2.56E+07 72.39 5.09 
CD8+ - 2.01E+08 3.21E+07 10.04 1.06 2.05E+08 2.67E+07 9.79 0.62 
CD44high CD62llow 3.41E+06 6.46E+05 1.75 0.47 4.69E+06 2.19E+06 2.31 1.13 
CD44low CD62lhigh 1.93E+08 3.21E+07 96.20 0.94 1.95E+08 2.79E+07 94.93 2.77 
CD19
+ - 1.36E+09 2.34E+08 69.26 2.65 1.40E+09 1.92E+08 67.86 2.63 
 IgMhigh 1.36E+09 2.34E+08 98.14 0.31 1.40E+09 1.92E+08 98.02 0.29 
NK - 4.93E+05* 8.21E+04 2.41* 0.30 7.46E+05* 1.17E+05 3.47* 0.21 
 636 
Mean (AVG) + standard deviation (SD) for cells from WT and Ifi27l2a-/- mice (n = 5 mice each, *, 637 
P < 0.05). The percentage of indicated populations are calculated as a proportion of the total 638 
parent population. 639 
 640 
  641 
 31
Table 2. Immunophenotyping of myeloid cells in peripheral blood of naïve WT and 642 
Ifi27l2a-/- mice. 643 
 644 
   WT Ifi27l2a-/- 
   Absolute Percent Absolute Percent 
Subset AVG +SD AVG +SD AVG +SD AVG +SD 
Monocyte - 2.31E+05 2.90E+04 7.54 0.52 2.72E+05 1.03E+05 8.98 2.50 
Gr-1high  1.68E+05 2.60E+04 72.62 3.68 1.96E+05 9.22E+04 70.58 5.44 
Gr-1low  6.17E+04 8.17E+03 26.90 3.73 7.49E+04 1.58E+04 29.04 5.48 
Neutrophil - 3.53E+05 1.30E+05 11.20 2.44 3.16E+05 9.53E+04 10.48 2.02 
Eosinophil - 3.07E+04 1.84E+04 0.96 0.41 3.02E+04 1.78E+04 0.99 0.47 
 645 
 646 
Number of cells per ml blood (AVG) + standard deviation (SD) from WT and Ifi27l2a-/- (n = 5) 647 




Table 3. Serum cytokine levels at days 4 and 6 after subcutaneous inoculation of WNV. 651 
 652 
   4 dpi 6 dpi 
   WT Ifi27l2a-/- WT Ifi27l2a-/- 
 LOD MEAN SD MEAN SD MEAN SD MEAN SD 
IL-1α 4.66 6.4 4.7 4.6 0.8 5.4 1.3 4.7 0.0 
IL-1β 32.95 182.2* 88.2 60.1* 44.0 53.2 43.6 78.9 145.8 
IL-2 2.92 19.4 8.6 27.0 10.4 19.1 14.2 16.3 10.6 
IL-3 1.32 4.7 2.6 2.8 1.4 2.9 1.0 1.9 1.2 
IL-4 6.11 7.2 2.0 5.7 1.2 5.3 1.6 5.7 4.6 
IL-5 1.76 91.8 190.4 23.1 6.1 29.9 20.8 22.1 12.0 
IL-6 0.86 26.1 55.4 5.5 0.9 10.9 16.2 5.2 2.5 
IL-9 26.47 26.5 0.0 26.5 0.0 26.5 0.0 26.5 0.0 
IL-10 6.32 62.3 40.9 47.6 20.3 38.1 19.2 24.0 14.5 
IL-12(p40) 1.7 229.5 114.9 179.2 54.0 151.5 46.4 134.2 27.2 
IL-12(p70) 0.99 34.1 16.3 24.5 9.3 19.5 14.4 8.4 8.2 
IL-13 63.51 212.9 54.2 162.3 57.9 178.0 57.6 144.8 18.7 
IL-17 2.94 29.7 16.4 28.6 7.9 25.2 10.9 26.7 13.4 
Eotaxin 38.95 454.6* 90.9 370.2* 157.6 371.8 125.7 379.5 138.4 
G-CSF 4.11 39.5 13.6 26.4 8.7 36.7 11.9 16.8 6.8 
GM-CSF 51.12 116.2 29.4 78.0 35.9 96.1 24.5 61.0 32.8 
IFN-γ 1.55 5.7 1.6 4.6 1.5 3.9 1.9 3.3 1.3 
KC 1.43 97.1 48.0 120.6 44.4 66.2 35.9 67.1 35.3 
MCP-1 15.39 156.3 54.0 147.5 20.1 130.7 46.6 110.7 39.3 
MIP-1α 1.76 11.2 2.6 10.9 1.3 9.8 2.0 8.6 2.4 
MIP-1β 6.81 41.1 38.8 24.4 8.7 15.5 10.6 17.1 14.7 
RANTES 0.81 34.6 8.1 32.5 12.6 33.8 10.9 37.4 15.4 
TNF-α 3.01 148.2 110.4 97.7 27.5 98.6 33.5 82.9 21.5 
 653 
 654 
Cytokine levels were assayed via Bioplex Pro to determine relative differences between WT and 655 
Ifi27l2a-/- mice (n = 8 to 9 mice per genotype per time point) at 4 and 6 days after infection of 102 656 
FFU by subcutaneous route. Data is the mean + standard deviation (SD). Levels were 657 
compared between WT and Ifi27l2a-/- by Student’s t-test (P < 0.05), with correction for multiple 658 
comparisons with Holm-Sidak method. LOD = Limit of Detection for each cytokine based on 659 
manufacture’s protocol for establishing standard curves for each parameter measured.  660 
  661 
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